Experimental drug combo takes on rare sarcomas

NCT ID NCT07027423

Not yet recruiting Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new drug called BOLD-100 combined with standard chemotherapy (doxorubicin) in 32 people with advanced soft tissue sarcomas that cannot be removed by surgery or have spread. The goal is to find the safest dose and see if the combination can shrink tumors or slow the cancer. Participants get the drugs intravenously in 21-day cycles, with scans every 12 weeks to check response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BOLD-100 (a ruthenium-based drug) combined with doxorubicin (chemotherapy)
What this could lead to: If it works, this could lead to a new treatment option for advanced soft tissue sarcomas that may help control the disease longer.
What could go wrong: This is a very early Phase 1b trial with only 32 people, so it's mainly checking safety and dosing. It may not show strong anti-cancer effects, and side effects from the combination are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEDIFFERENTIATED LIPOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dedifferentiated liposarcoma leiomyosarcoma myxofibrosarcoma sarcoma soft tissue sarcoma undifferentiated pleomorphic sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARCOMA SARCOMA,SOFT TISSUE SARCOMAS

Contacts and locations

Locations

UHN- Princess Margaret Cancer Center

Toronto, Ontario, M5G 1Z5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.